EuBiologics Co., Ltd. (KOSDAQ:206650)
South Korea
· Delayed Price · Currency is KRW 13,160
-160 (-1.20%)
Apr 29, 2026, 1:30 PM KST
EuBiologics Revenue
In the year 2024, EuBiologics had annual revenue of 96.04B KRW with 38.45% growth. EuBiologics had revenue of 26.89B in the quarter ending December 31, 2023, with 54.38% growth.
Revenue
96.04B
Revenue Growth
+62.39%
P/S Ratio
5.09
Revenue / Employee
n/a
Employees
n/a
Market Cap
489.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 96.04B | 26.67B | 38.45% |
| Dec 31, 2023 | 69.37B | 13.90B | 25.06% |
| Dec 31, 2022 | 55.47B | 16.08B | 40.83% |
| Dec 31, 2021 | 39.38B | 10.90B | 38.24% |
| Dec 31, 2020 | 28.49B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dong-A ST | 808.78B |
| FutureChem Co.,Ltd | 18.67B |
| Shinpoong Pharmaceutical Co.,Ltd | 234.68B |
| Dong-A Socio Holdings | 1,429.77B |
| Humedix | 110.99B |
| JW Pharmaceutical | 775.30B |
| Yungjin Pharm. | 158.79B |
| Bukwang Pharmaceutical | 200.71B |